1Jaffe E, Harris N, Stein H, et al. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press. 2001: 171-175.
2Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin' s disease: Cotswolds meeting. J Clin Oncol, 1989, 7 : 1630-1636.
3Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by im- munohistochemistry using a tissue microarray. Blood, 2004,103 : 275 -282.
4Ke X, Wang J, Gao Z, et al. Clinical characteristics and prognos- tic analysis of Chinese patients with diffuse large B-cell lymphoma. Blood Cells Mol Dis, 2010, 44: 55-61.
5Kim MK, Bae S I-i, Bae YK, et al. Biological characterization of nodal versus extranodal presentation of diffuse large B-cell lympho- ma using immunohistochemistry. Clin Lymphoma Myeloma Leuk, 2011,11 : 403-408.
6Chen Z, Du Z, Chen J, et al. Prognostic evaluation of immuno- histochemical profiles in diffuse large B-cell lymphoma: a Chinese study. Med Oncol, 2011, 28: 241-248.
7Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol,2010,11 : 827-834.
8Shiozawa E, Yamochi-Onizuka T, Takimoto M, et al. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res, 2007, 31: 1579-1583.
9Song Y, Cao Z, Su Q, et al. Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 pa-tients with diffuse large B-cell lymphoma.2009, 8: 585-591.
10Zhang I-IW, Chen ZW, Li SH, et al. Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma. Hematol Oncol, 2011, 29: 185-189.
